Anxiety disorder is a comorbid condition of chronic pain. Analgesics and anxiolytics, subject to addiction and abuse, are currently used to manage pain and anxiety symptoms. However, the cellular mechanism underlying chronic pain and anxiety interaction remains to be elucidated. We report that persistent nociception following peripheral nerve injury induced anxiety-like behavior in rodents. Brain expression and release of neuropeptide S (NPS), a proposed endogenous anxiolytic peptide, was diminished in rodents with coexisting nociceptive and anxiety-like behaviors. Intracerebroventricular administration of exogenous NPS concurrently improved both nociceptive and anxiety-like behaviors. At the cellular level, NPS enhanced intra-amygdaloidal inhibitory transmission by increasing presynaptic gammaaminobutyric acid (GABA) release from interneurons. These findings indicate that the interaction between nociceptive and anxiety-like behaviors in rodents may be regulated by the altered NPSmediated intra-amygdaloidal GABAergic inhibition. The data suggest that enhancing the brain NPS function may be a new strategy to manage comorbid pain and anxiety. Ó
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Introduction
Epidemiological studies have shown that pain and anxiety disorders are closely linked in the clinical setting [4, 19, 54] , showing a reciprocal, comorbid relationship in longitudinal (>3 years) studies [2] . The prevalence of anxiety disorders in patients with chronic pain ranges from 20% to 51% [19, 28, 32, 48] , which is much higher than that of 10% to 15% in the general population [20, 26] . Compared to patients with acute pain (<3 months), those with chronic pain (>1 year) have significantly higher anxiety scores and less pain reduction at a 1-year follow-up [40] . Moreover, improving clinical anxiety is accompanied by a parallel decrease in pain intensity [51] . Despite this well-documented clinical association between pain and anxiety, the underlying mechanism of their comorbid interaction remains to be elucidated. Currently, analgesics and anxiolytics, subject to addiction and abuse, remain the mainstay in managing symptoms of both conditions.
Recently, 20-amino acid neuropeptide S (NPS) has been shown to be a prominent endogenous anxiolytic in rodents [24, 60] without affecting depressive behavior [58] . A study in naive rodents suggests that NPS mediates anxiolytic effects through a GABAergic mechanism in the amygdala [25] . NPS binds to its cognate receptor NPS receptor (NPSR) [46] to modulate anxiety, arousal, memory, and immune response. Abnormal NPS-NPSR signaling caused by NPSR gene mutation or polymorphism has been associated with pathological conditions including panic disorder [14, 41] , catastrophizing [45], asthma [6] , and rheumatoid arthritis [1] in human subjects. Another study in mice revealed the antinociceptive effect of NPS on inflammatory pain [44] . The amygdala has been implicated in the integration of pain and mood disorders [3, 8, 12, 61] . NPS-responsive neurons express NPSR and are concentrated in the amygdala [11, 59] . Moreover, GABAergic transmission regulates both anxiety [17, 34, 39] and pain [36] .
We hypothesize that NPS-mediated gamma-aminobutyric acid (GABA) transmission in amygdala may play a role in the interaction 
